Literature DB >> 11264375

Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.

J H Ahn1, Y Xu, W J Jang, M J Matunis, G S Hayward.   

Abstract

The human cytomegalovirus (HCMV) major immediate-early protein IE2 is a nuclear phosphoprotein that is believed to be a key regulator in both lytic and latent infections. Using yeast two-hybrid screening, small ubiquitin-like modifiers (SUMO-1, SUMO-2, and SUMO-3) and a SUMO-conjugating enzyme (Ubc9) were isolated as IE2-interacting proteins. In vitro binding assays with glutathione S-transferase (GST) fusion proteins provided evidence for direct protein-protein interaction. Mapping data showed that the C-terminal end of SUMO-1 is critical for interaction with IE2 in both yeast and in vitro binding assays. IE2 was efficiently modified by SUMO-1 or SUMO-2 in cotransfected cells and in cells infected with a recombinant adenovirus expressing HCMV IE2, although the level of modification was much lower in HCMV-infected cells. Two lysine residues at positions 175 and 180 were mapped as major alternative SUMO-1 conjugation sites in both cotransfected cells and an in vitro sumoylation assay and could be conjugated by SUMO-1 simultaneously. Although mutations of these lysine residues did not interfere with the POD (or ND10) targeting of IE2, overexpression of SUMO-1 enhanced IE2-mediated transactivation in a promoter-dependent manner in reporter assays. Interestingly, many other cellular proteins identified as IE2 interaction partners in yeast two-hybrid assays also interact with SUMO-1, suggesting that either directly bound or covalently conjugated SUMO moieties may act as a bridge for interactions between IE2 and other SUMO-1-modified or SUMO-1-interacting proteins. When we investigated the intracellular localization of SUMO-1 in HCMV-infected cells, the pattern changed from nuclear punctate to predominantly nuclear diffuse in an IE1-dependent manner at very early times after infection, but with some SUMO-1 protein now associated with IE2 punctate domains. However, at late times after infection, SUMO-1 was predominantly detected within viral DNA replication compartments containing IE2. Taken together, these results show that HCMV infection causes the redistribution of SUMO-1 and that IE2 both physically binds to and is covalently modified by SUMO moieties, suggesting possible modulation of both the function of SUMO-1 and protein-protein interactions of IE2 during HCMV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264375      PMCID: PMC114877          DOI: 10.1128/JVI.75.8.3859-3872.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p.

Authors:  E S Johnson; G Blobel
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.

Authors:  T Durfee; K Becherer; P L Chen; S H Yeh; Y Yang; A E Kilburn; W H Lee; S J Elledge
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

3.  Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.

Authors:  H Li; C Leo; J Zhu; X Wu; J O'Neil; E J Park; J D Chen
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  c-Jun and p53 activity is modulated by SUMO-1 modification.

Authors:  S Muller; M Berger; F Lehembre; J S Seeler; Y Haupt; A Dejean
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

5.  Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9.

Authors:  L Gong; T Kamitani; K Fujise; L S Caskey; E T Yeh
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

6.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Transactivation by the human cytomegalovirus IE2 86-kilodalton protein requires a domain that binds to both the TATA box-binding protein and the retinoblastoma protein.

Authors:  M H Sommer; A L Scully; D H Spector
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site.

Authors:  Y D Yoo; C J Chiou; K S Choi; Y Yi; S Michelson; S Kim; G S Hayward; S J Kim
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Functional interaction between the HCMV IE2 transactivator and the retinoblastoma protein.

Authors:  C Hagemeier; R Caswell; G Hayhurst; J Sinclair; T Kouzarides
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

10.  The human cytomegalovirus 86K immediate early (IE) 2 protein requires the basic region of the TATA-box binding protein (TBP) for binding, and interacts with TBP and transcription factor TFIIB via regions of IE2 required for transcriptional regulation.

Authors:  R Caswell; C Hagemeier; C J Chiou; G Hayward; T Kouzarides; J Sinclair
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

View more
  42 in total

1.  Characterization of a human cytomegalovirus with phosphorylation site mutations in the immediate-early 2 protein.

Authors:  Julie A Heider; Yongjun Yu; Thomas Shenk; James C Alwine
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity.

Authors:  Darja Schmidt; Stefan Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

3.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Role of the specific interaction of UL112-113 p84 with UL44 DNA polymerase processivity factor in promoting DNA replication of human cytomegalovirus.

Authors:  Young-Eui Kim; Jin-Hyun Ahn
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 5.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

6.  SUMOylation of the human cytomegalovirus 72-kilodalton IE1 protein facilitates expression of the 86-kilodalton IE2 protein and promotes viral replication.

Authors:  Michael Nevels; Wolfram Brune; Thomas Shenk
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins.

Authors:  José González-Santamaría; Michela Campagna; María Angel García; Laura Marcos-Villar; Dolores González; Pedro Gallego; Fernando Lopitz-Otsoa; Susana Guerra; Manuel S Rodríguez; Mariano Esteban; Carmen Rivas
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

8.  SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.

Authors:  An-Jing Chen; Lu Gao; Xian-Wei Wang; Xiao-Fan Zhao; Jin-Xing Wang
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.

Authors:  Y Xu; J H Ahn; M Cheng; C M apRhys; C J Chiou; J Zong; M J Matunis; G S Hayward
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Casein kinase-2-mediated phosphorylation increases the SUMO-dependent activity of the cytomegalovirus transactivator IE2.

Authors:  Vasvi Tripathi; Kiran Sankar Chatterjee; Ranabir Das
Journal:  J Biol Chem       Date:  2019-08-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.